Grace Therapeutics, Inc.

Listed Company

GRCECIK 0001444192NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Mar 31

Period

FY 2025

Revenue

—

Net Income

$-9.57M

Total Assets

$71.99M

Equity

$66.61M

Shares Out

15.47M

Op. Cash Flow

$-14.90M

Business

Grace Therapeutics, Inc. develops and commercializes reformulated pharmaceutical products for rare and orphan diseases using proprietary drug delivery and formulation technologies. Its main product candidates are three clinical-stage therapies: GTx-104 (an intravenous nanoparticle formulation of nimodipine for aneurysmal subarachnoid hemorrhage), GTx-102 (an oral‑mucosal betamethasone spray for ataxia‑telangiectasia), and GTx-101 (a topical bio‑adhesive bupivacaine spray for postherpetic neuralgia). The company operates research, clinical development, regulatory and intellectual property functions and relies on third‑party CMOs for manufacturing. It targets hospital and specialty physician channels in the United States while pursuing international patent protection and potential commercial partnerships and licensing for broader distribution.

Summary from filing dated 2025-06-23

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31
Research and development expenses, net of government assistance	−10	−5	−10	−6	−4
General and administrative expenses	−7	−7	−8	−9	−6
Restructuring cost	0	−1	0	—	—
Loss from operating activities	−17	−13	−52	−16	−16
Foreign exchange (loss) gain	−17,000	−16,000	−72,000	—	—
Change in fair value of derivative warrant liabilities	3	−3	10,000	—	—
Interest and other income, net	711,000	911,000	246,000	—	—
Total other income, net	4	−2	184,000	5	−3
Loss before income tax benefit	−13	−15	−52	−10	−20
Income tax benefit	3	2	10	648,000	0
Net loss	−10	−13	−42	−10	−20
Total comprehensive loss	−10	−13	—	—	—
Basic loss per share (in Dollars per share)	−0.79	−1.35	−5.71	−0.27	—
Diluted loss per share (in Dollars per share)	−0.79	−1.35	−5.71	−0.27	—
Weighted average number of shares outstanding, basic (in Shares)	12	10	7	37	—
Weighted average number of shares outstanding, diluted (in Shares)	12	10	7	37	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31
Cash and cash equivalents	22	23	28	30	51
Receivables	126,000	722,000	—	—	—
Prepaid expenses	453,000	283,000	598,000	720,000	343,000
Total current assets	23	24	29	45	62
Equipment, net	15,000	24,000	104,000	250,000	—
Intangible assets	41	41	41	70	—
Goodwill	8	8	8	13	—
Total assets	72	73	79	129	62
Trade and other payables	2	2	3	3	1
Total current liabilities	2	2	3	3	2
Derivative warrant liabilities	1	4	0	10,000	5
Deferred tax liability	2	6	7	17	—
Total liabilities	5	12	11	20	7
Commitments and contingencies (Note 13)	—	—	—	—	—
Preferred stock, $0.0001 par value per share; 10,000,000 authorized, none issued and outstanding as of March 31, 2025 and 2024	0	0	—	—	—
Common stock, $0.0001 par value per share; 100,000,000 authorized; 13,718,106 and 9,399,404 shares issued and outstanding as of March 31, 2025 and 2024, respectively	1,000	1,000	258	258	197
Additional paid-in capital	293	279	14	12	11
Accumulated other comprehensive loss	−6	−6	−6	−6	−6
Accumulated deficit	−221	−211	−198	−156	−146
Total stockholders' equity	67	62	68	108	56
Total liabilities and stockholders equity	72	73	79	129	62

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31
Depreciation expense	7,000	11,000	124,000	0	143,000
Gain on sale of equipment	0	−59,000	0	—	—
Loss on disposal	2,000	39,000	—	—	—
Stock-based compensation	730,000	913,000	2	1	1
Receivables	596,000	80,000	−302,000	—	—
Prepaid expenses	−170,000	315,000	72,000	—	—
Trade and other payables	−84,000	−2	411,000	—	—
Operating lease right of use asset	0	−23,000	0	—	—
Net cash used in operating activities	−15	−12	−16	−17	−14
Maturity of short-term investments	15,000	7	18	31	21,000
Purchase of short-term investments	−15,000	−7	−5	−35	−10
Purchase of equipment	0	−22,000	−17,000	—	—
Sale of equipment	0	111,000	—	—	—
Net cash provided by investing activities	0	104,000	13	−4	−10
Gross proceeds from issuance of common stock and warrants from private placement	15	8	—	—	—
Stock issuance costs	−967,000	−162,000	—	—	—
Proceeds from issuance of common stock from exercise of stock options	0	21,000	—	0	118,000
Net cash provided by financing activities	14	7	304,000	0	59
Net decrease in cash and cash equivalents	−872,000	−5	−2	−21	37
Issuance costs in accounts payable	327,000	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro